Manufacturer
Fresenius Kabi Oncology Limited (XI Route)
Contents
Fludarabine phosphate
Indication
B cell chronic lymphocytic leukaemia.
Instruction
Adult: 25 mg/m2 daily via bolus inj or infusion over 30 min for 5 consecutive days. Courses may be repeated every 28 days, usually for up to 6 cycles. Dosage may be adjusted based on evidence of haematologic or non-haematologic toxicity.
Drug interaction
Reduced therapeutic effect w/ dipyridamole and other inhibitors of adenosine uptake. Cytarabine may reduce the metabolic activation of fludarabine. May diminish the effect of live vaccines.Potentially Fatal: Increased risk of severe pulmonary toxicity when used in combination w/ pentostatin.
Malaysia
